Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment.

Angela Genge,Gary L Pattee,Gen Sobue,Masashi Aoki,Hiide Yoshino,Philippe Couratier,Christian Lunetta,Susanne Petri,Daniel Selness,Sachin Bidani,Manabu Hirai,Takeshi Sakata,Alejandro Salah,Stephen Apple,Art Wamil,Alexander Kalin,Carlayne E Jackson

Muscle & nerve（2023）

引用 6|浏览34

暂无评分

摘要

This study indicated that oral edaravone was well tolerated during 48 wk of treatment, with no new safety concerns identified.

更多

查看译文

关键词

amyotrophic lateral sclerosis,clinical trials,edaravone,motor neuron disease,safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要